References
- Arjomand A. (2010). Accelerator mass spectrometry-enabled studies: current status and future prospects. Bioanalysis 2:519–41
- Bibbiani F, Oh JD, Petzer JP, et al. (2003). A2a antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol 184:285–94
- Garner RC. (2000). Accelerator mass spectrometry in pharmaceutical research and development-a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1:205–13
- Garner RC, Barker J, Flavell C, et al. (2000). A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 24:197–209
- Hah SS, Henderson PT, Turteltaub KW. (2009). Recent advances in biomedical applications of accelerator mass spectrometry. J Biomed Sci 16:111
- Hamilton RA, Garnett WR, Kline BJ. (1981). Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–13
- Hop CE, Wang Z, Chen Q, Kwen G. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3
- Hauser RA, Olanow CW, Kieburtz KD, et al. (2014). Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomized trial. Lancet Neurol 13:767–76
- Jenner P, Mori A, Hauser R, et al. (2009). Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 15:406–13
- Lappin G, Stevens L. (2008). Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol 4:1021–33
- Pinna A. (2009). Novel investigational adenosine A2A receptor antagonists for Parkinson’s disease. Expert Opin Investig Drugs 18:1619–31
- Roffey SJ, Obach RS, Gedge JI, Smith DA. (2007). What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43
- Salehpour M, Possnert G, Bryhni H. (2008). Subattomole sensitivity in biological accelerator mass spectrometry. Anal Chem 80:3515–21
- Sarapa N, Hsyu PH, Lappin G, Garner RC. (2005). The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers. J Clin Pharmacol 45:1198–205
- Schwarzschild MA, Xu K, Oztas E, et al. (2003). Neuroprotection by caffeine and more specific A2a receptor antagonists in animal models of Parkinson's disease. Neurology 61:S55–61
- Snyder WS, Cook MJ, Karhausen LR, et al. (1975). Report of the task group on reference man. ICRP publication no.23. Oxford, UK: Elsevier Science Ltd., 340
- Tse S, Leung L, Raje S, et al. (2014). Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry. Drug Metab Dispos 42:2023–32
- Vogel JS. (1992). Rapid production of graphite without contamination for biomedical AMS. Radiocarbon 34:344–50
- Yu L, Schwarzschild MA, Chen JF. (2006). Cross-sensitization between caffeine- and Ldopa induced behaviors in hemiparkinsonian mice. Neurosci Lett 393:31–5